Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
Open Access
- 29 September 2023
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-10
Abstract
Respiratory syncytial virus (RSV) causes a high disease burden in older adults. An effective vaccine for this RSV-primed population may need to boost/elicit robust RSV-neutralizing antibody responses and recall/induce RSV-specific T cell responses. To inform the selection of the vaccine formulation for older adults, RSVPreF3 (RSV fusion glycoprotein engineered to maintain the prefusion conformation) with/without AS01 adjuvant was evaluated in mice and bovine RSV infection-primed cattle. In mice, RSVPreF3/AS01 elicited robust RSV-A/B-specific neutralization titers and RSV F-specific polyfunctional CD4+ T cell responses exceeding those induced by non-adjuvanted RSVPreF3. In primed bovines, RSVPreF3/AS01 tended to induce higher pre-/post-vaccination fold-increases in RSV-A/B-specific neutralization titers relative to non-adjuvanted and Alum-adjuvanted RSVPreF3 formulations, and elicited higher RSV F-specific CD4+ T cell frequencies relative to the non-adjuvanted vaccine. Though AS01 adjuvanticity varied by animal species and priming status, RSVPreF3/AS01 elicited/boosted RSV-A/B-specific neutralization titers and RSV F-specific CD4+ T cell responses in both animal models, which supported its further clinical evaluation as prophylactic candidate vaccine for older adults.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA. Grant Reference number: N/A
This publication has 56 references indexed in Scilit:
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyScience, 2013
- Strategic priorities for respiratory syncytial virus (RSV) vaccine developmentVaccine, 2013
- Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in miceVaccine, 2012
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersProceedings of the National Academy of Sciences, 2011
- Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjectsImmunity & Ageing, 2010
- Variation matters: TLR structure and species-specific pathogen recognitionTrends in Immunology, 2009
- Host species-specific usage of the TLR4-LPS receptor complexInnate Immunity, 2008
- Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4+ T cells in humansMechanisms of Ageing and Development, 2006
- Pre-clinical evaluation of the malaria vaccine candidate . MSP1 formulated with novel adjuvants or with alumVaccine, 2004
- Effect of Aging on Cytokine Production in Response to Respiratory Syncytial Virus InfectionThe Journal of Infectious Diseases, 2002